Search
for
Sort by
Research
180-210 / 1000+ results
research Increased serum interleukin-17A levels correlate with disease severity and poor prognostic factors in patients with alopecia areata
Higher IL-17A levels indicate more severe alopecia areata.
research Lupus eritematoso cutáneo y su asociación con actividad sistémica
More skin lesions in lupus patients may indicate higher disease activity.
research Rethinking the classification of alopecia areata
The document concludes that a new system using the SALT score should replace the current alopecia areata classification for better accuracy in assessing severity and prognosis.
research Evaluation of the level of serum Interleukins (IL-2, IL-4, IL-15 andIL-17) and its relationship with disease severity in patients with alopecia areata
Interleukin levels are higher in alopecia areata patients but don't predict disease severity or duration.
research Simultaneous improvement of alopecia universalis and atopic dermatitis in a patient treated with a JAK inhibitor
A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.
research Determining meaningful thresholds for evaluating treatment efficacy in patients with alopecia areata
A change in SALT scores of 42 or 43 indicates meaningful improvement in alopecia areata treatment.
research Multiomic Characterization of Treatment Response to JAK Inhibition in Patients with APECED
Ruxolitinib reduced inflammation and improved symptoms in APECED patients but may cause anemia and weight gain.
research Low disease activity—irrespective of serologic status at baseline—associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study
Belimumab reduces disease activity, steroid use, and flares in lupus patients.
research Efficacy and safety of tofacitinib in patients with alopecia areata
Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.
research P07 Pityriasis amiantacea: a unique presentation of psoriasis associated with tumour necrosis factor-α inhibitor therapy
A woman's rare scalp condition worsened after using a specific arthritis medication, suggesting such medications can sometimes trigger or aggravate psoriasis.
research Item-specific patterns of the Skindex-17 in individuals with different levels of Hidradenitis Suppurativa severity: a network analysis study
Addressing psychosocial symptoms can improve outcomes for people with Hidradenitis Suppurativa.
research 0475 High-dose UVA-1 therapy improves patient-reported outcomes and clinical scores in patients with sclerosing skin disease
High-dose UVA-1 therapy improves symptoms and skin condition in sclerosing skin disease.
research Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment
Anti-IL-12/IL-23 antibody therapy effectively treats psoriasiform skin lesions in IBD patients.
research Refractory folliculitis decalvans treated with adalimumab: A case series of 23 patients
Adalimumab improved folliculitis decalvans in most patients.
research 33774 Baricitinib results in eyebrow and eyelash growth in patients with alopecia areata who do not achieve 20% or less scalp hair loss
Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
research Findings from the assessment of real-world disease characteristics and outcomes in alopecia areata in a global non-interventional observational cohort (ADAAGIO) study
Most patients with alopecia areata did not achieve lasting hair regrowth despite treatment.
research The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta‐analyses of clinical trials
JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
research Complete Blood Collection-based Systemic Inflammation Biomarkers as a Severity Biomarker in Alopecia Areata: A Cross-sectional Study
Higher inflammation markers are linked to more severe alopecia areata.
research 127 Quality of life in patients with connective tissue diseases: results from the Lupus Extended Autoimmune Phenotype (LEAP) study
Many lupus patients experience hair loss, which is linked to anxiety and other skin issues.
research Cutaneous Involvement in Systemic Lupus Erythematosus: A Review for the Rheumatologist
Skin problems are common in lupus patients and should be treated early to prevent worsening.
research First‐degree relatives of patients with systemic lupus erythematosus: Autoreactivity but not autoimmunity?
Relatives of lupus patients show signs of immune system activity but not full-blown lupus.
research Baricitinib Effectiveness in JAKi‐Naïve and Tofacitinib‐Exposed Patients: A Prospective Study in Alopecia Areata
Baricitinib works better for alopecia areata in patients not previously treated with tofacitinib.
research Degree of Alignment Between Japanese Patients and Physicians on Alopecia Areata Disease Severity and Treatment Satisfaction: A Real-World Survey
Japanese patients and physicians often disagree on the severity of Alopecia Areata and treatment satisfaction, needing better communication and treatments.
research 0433 JAK inhibitor halts the progression of acute exacerbation of alopecia areata
Baricitinib stops hair loss and promotes regrowth in alopecia areata.
research 62202 Network meta-analysis (NMA) of FDA-approved JAK inhibitors for alopecia areata (AA) with at least 50% hair loss per SALT score
Some JAK inhibitors are effective for significant hair regrowth in alopecia areata.
research JAK Inhibitors in African American Patients With Alopecia Areata: A Case Series
JAK inhibitors effectively reduce alopecia areata symptoms in Black patients.
research Evaluation of the serum C‐reactive protein–albumin ratio and its relationship with disease severity IN alopecia areata: A prospective case–control study
CAR is a useful marker for assessing alopecia areata severity.
research This Month in JAAD: October 2021
Oral baricitinib is effective and safe for treating alopecia areata.
research A new self‐reported measure of disease severity of scalp hair loss in alopecia areata
The new measure helps understand the personal and emotional impact of hair loss in alopecia areata patients.